Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) in Padua, Italy, from May 12-16, 2026. The meeting, hosted by the University of Padova, focuses on advanced cardiovascular imaging and artificial intelligence—areas central to Ventripoint's VMS+™ technology.
AEPC, founded in 1963, is the largest congenital cardiology association globally, with over 1,000 specialists from 32 European countries. Ventripoint will share a booth with its European distributor, AngioPro, to engage clinicians and demonstrate VMS+™ 4.0, the latest version of its AI-powered echocardiography analysis platform. The system provides volumetric cardiac measurements equivalent to MRI but through a faster, more affordable ultrasound-based workflow.
The importance of longitudinal cardiac function monitoring in congenital heart disease (CHD) patients is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC. These guidelines identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for ventricular function assessment. VMS+™ directly addresses this need by enabling clinicians to obtain accurate volumetric data from a patient's first echocardiogram, supporting early and ongoing clinical decision-making.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI—giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint's priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice. The VMS+™ 4.0 release streamlines workflows, reduces assessment time, and makes advanced cardiac analysis accessible at the point of care. The platform is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada. By providing MRI-equivalent measurements early in the care journey, VMS+™ aims to improve patient management and outcomes for the growing population of CHD patients.
